This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Home Depot (HD) and Cisco (CSCO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
HD CBSH LMT CBSHP BSX NYLD VEEV TWX TWC NYLD.A CBCB BYD
40 of 104 Russell 3000 Index stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields.
ANH.PRA GEO GMRE.PRA ANH.PRC ANH.PRB ANH ORC LADR CIM GMRE CYS.PRA NYLD CLNS.PRDCL CYS.PRB CORR.PRA AGNC NYLD.A CORR CIM.PRA CLNS IVR.PRA IVR.PRB CLNS.PRJ CLNS.PRI IVR.PRC CLNS.PRH DX NLY GLPI NLY.PRA CLNS.PRG CLNS.PRE NLY.PRECL NLY.PRD CLNS.PRD NLY.PRE CIM.PRB CLNS.PRB CYS NLY.PRC NLY.PRF NLY.PRG IVR DX.PRB DX.PRA
Good morning. My name is Tiffany and I will be your conference operator today. At this time, I would like to welcome everyone to the FuelCell Energy's Second Quarter 2018 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
NRGEO HTGZ SOJA NRG SO NYLD FCELB HTGC NYLD.A HTGX FCEL HTGY
DANBURY, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq:FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, today reported financial results for the three and six-month periods ended April 30, 2018 and key business highlights.
NRGEO NRG NYLD FCELB NYLD.A FCEL
JE, SPKE, & SBS led the top ten WallStar Utilities per broker targeted price gains with combined 61.8% average net gains while 7 trailing combined for 24.5% average gains 5/23/18.
JE DUKH PEGI SCG SPKE AY DUK JE NYLD APU PPL PEG CAFD SPH NYLD.A JE.PRA TERP
Cheniere Energy (LNG) saw three upward target price revisions following its 1Q18 earnings. These changes could be due to an increase in its 2018 guidance.
TRP CQP CLMT LNG MS.PRE MS.PRF MS.PRG NEP MS.PRA MS.PRI MS.PRK NYLD CQH MS PLX NYLD.A
The S&P 500 headed slightly lower last week as a solid employment report on Friday helped the market recoup earlier losses. High expectations heading into earnings season, plus lingering trade war concerns and uncertainty over the Fed’s plans to raise rates, all weighed on sentiment. However, a handful of businesses added some good news with dividend increases.
SOHOL NYLD AAPL SOHOB SOHO CHCT TRTN NYLD.A SOHOM
Good day, ladies and gentlemen, and welcome to the NRG Yield First Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this call is being recorded.
NRGEO NRG DB NYLD NYLD.A
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET